KR20140146036A - 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법 - Google Patents

피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20140146036A
KR20140146036A KR1020147001774A KR20147001774A KR20140146036A KR 20140146036 A KR20140146036 A KR 20140146036A KR 1020147001774 A KR1020147001774 A KR 1020147001774A KR 20147001774 A KR20147001774 A KR 20147001774A KR 20140146036 A KR20140146036 A KR 20140146036A
Authority
KR
South Korea
Prior art keywords
cancer
composition
compound
cell
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147001774A
Other languages
English (en)
Korean (ko)
Inventor
히로시 야마코세
타카푸미 카토
Original Assignee
아르퀼 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르퀼 인코포레이티드 filed Critical 아르퀼 인코포레이티드
Publication of KR20140146036A publication Critical patent/KR20140146036A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147001774A 2011-07-07 2012-07-06 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법 Withdrawn KR20140146036A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505175P 2011-07-07 2011-07-07
US61/505,175 2011-07-07
PCT/US2012/045688 WO2013006761A2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Publications (1)

Publication Number Publication Date
KR20140146036A true KR20140146036A (ko) 2014-12-24

Family

ID=47437711

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147001774A Withdrawn KR20140146036A (ko) 2011-07-07 2012-07-06 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법

Country Status (14)

Country Link
US (2) US9180099B2 (cg-RX-API-DMAC7.html)
EP (1) EP2729145A4 (cg-RX-API-DMAC7.html)
JP (1) JP6073310B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140146036A (cg-RX-API-DMAC7.html)
CN (1) CN103930110A (cg-RX-API-DMAC7.html)
AU (1) AU2012278831A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013033807A2 (cg-RX-API-DMAC7.html)
CA (1) CA2839584A1 (cg-RX-API-DMAC7.html)
IN (1) IN2013MN02443A (cg-RX-API-DMAC7.html)
MX (1) MX2014000253A (cg-RX-API-DMAC7.html)
PH (2) PH12014500055A1 (cg-RX-API-DMAC7.html)
TW (1) TW201315470A (cg-RX-API-DMAC7.html)
WO (1) WO2013006761A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400108B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100941205B1 (ko) * 2005-02-09 2010-02-10 아르퀼 인코포레이티드 말레이미드 유도체, 약제학적 조성물 및 암을 치료하는방법
WO2013162714A1 (en) * 2012-04-23 2013-10-31 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
KR100786927B1 (ko) * 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
KR100941205B1 (ko) 2005-02-09 2010-02-10 아르퀼 인코포레이티드 말레이미드 유도체, 약제학적 조성물 및 암을 치료하는방법
ES2434072T3 (es) 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CA2645566A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
CN101474175B (zh) * 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
TWI460178B (zh) 2009-02-12 2014-11-11 Arqule Inc 組合性組成物及治療癌症之方法
MY156701A (en) 2009-12-23 2016-03-15 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
PH12015501980A1 (en) 2017-10-18
TW201315470A (zh) 2013-04-16
US9180099B2 (en) 2015-11-10
CN103930110A (zh) 2014-07-16
WO2013006761A3 (en) 2013-04-18
AU2012278831A1 (en) 2014-01-16
EP2729145A4 (en) 2014-12-10
US20130011481A1 (en) 2013-01-10
BR112013033807A2 (pt) 2017-02-14
JP2014518284A (ja) 2014-07-28
PH12014500055A1 (en) 2016-02-08
JP6073310B2 (ja) 2017-02-01
WO2013006761A2 (en) 2013-01-10
CA2839584A1 (en) 2013-01-10
IN2013MN02443A (cg-RX-API-DMAC7.html) 2015-06-12
US20160022667A1 (en) 2016-01-28
MX2014000253A (es) 2014-10-17
ZA201400108B (en) 2016-03-30
EP2729145A2 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
JP5687209B2 (ja) 第２の抗増殖剤と組み合わせて（−）−ｔｒａｎｓ−３−（５，６−ジヒドロ−４Ｈ−ピロロ［３，２，１−ｉｊ］キノリン−１−イル）−４−（１Ｈ−インドール−３−イル）ピロリジン−２，５−ジオンを含有する組成物
TW202038951A (zh) 用於治療癌症之醫藥組合
EP2558085B1 (en) Compositions and methods for the prevention and treatment of cancer
US8575191B2 (en) Methods for treatment of non-small cell lung cancer
TW201945340A (zh) 治療癌症之方法
US8580764B2 (en) Combinational compositions and methods for treatment of cancer
KR20140146036A (ko) 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
US20110301194A1 (en) Method for Determining Treatment Efficacy
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
HK1164159B (en) A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
TW201215610A (en) Combinational compositions and methods for treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid